Source link : https://san-francisco-news.com/2025/10/25/spruce-biosciences-earns-fda-breakthrough-therapy-designation-for-promising-sanfilippo-syndrome-type-b-treatment/
Spruce Biosciences has received FDA Breakthrough Therapy Designation for Tralesinidase Alfa (TA-ERT), an enzyme replacement therapy targeting Sanfilippo Syndrome Type B (MPS IIIB), advancing treatment prospects for this rare disorder.
—-
Author : William Green
Publish date : 2025-10-25 08:30:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8
in News